+

WO2001096377A3 - Vaccin contre les tremblements congenitaux du porc - Google Patents

Vaccin contre les tremblements congenitaux du porc Download PDF

Info

Publication number
WO2001096377A3
WO2001096377A3 PCT/US2001/019220 US0119220W WO0196377A3 WO 2001096377 A3 WO2001096377 A3 WO 2001096377A3 US 0119220 W US0119220 W US 0119220W WO 0196377 A3 WO0196377 A3 WO 0196377A3
Authority
WO
WIPO (PCT)
Prior art keywords
pcv
pig
congenital tremors
pigs
polypeptide
Prior art date
Application number
PCT/US2001/019220
Other languages
English (en)
Other versions
WO2001096377A2 (fr
Inventor
Suresh K Mittal
Gregory W Stevenson
Jiwon Choi
Matti Kiupel
Charles L Kanitz
Original Assignee
Purdue Research Foundation
Suresh K Mittal
Gregory W Stevenson
Jiwon Choi
Matti Kiupel
Charles L Kanitz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation, Suresh K Mittal, Gregory W Stevenson, Jiwon Choi, Matti Kiupel, Charles L Kanitz filed Critical Purdue Research Foundation
Priority to CA002410229A priority Critical patent/CA2410229A1/fr
Priority to AU2001266940A priority patent/AU2001266940A1/en
Priority to EP01944540A priority patent/EP1290016A2/fr
Priority to MXPA02012352A priority patent/MXPA02012352A/es
Priority to JP2002510517A priority patent/JP2004503234A/ja
Priority to US10/311,423 priority patent/US20040071728A1/en
Publication of WO2001096377A2 publication Critical patent/WO2001096377A2/fr
Publication of WO2001096377A3 publication Critical patent/WO2001096377A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention repose sur le clonage de souches du circovirus porcin (CVP) provenant de porcs atteints de tremblements congénitaux. L'invention constitue une première étape dans la mise au point d'applications diagnostiques et thérapeutiques destinées à traiter les tremblements congénitaux chez les porcs. Le procédé diagnostique de l'invention consiste à déterminer si le porc a été infecté par une souche de circovirus porcin de type 1 ou de type 2. L'invention concerne également un procédé permettant de traiter ou de prévenir les tremblements congénitaux chez le porc, selon lequel on administre au porc une quantité efficace d'un polypeptide immunogène de CVP1 ou CVP2 ou d'un acide nucléique codant ledit polypeptide. L'invention concerne également de nouvelles séquences d'acide nucléique du CVP qui ont été identifiées par les inventeurs et les polypeptides codés par ces séquences, ainsi que de nouveaux isolats de CVP et des préparations immunogènes fabriquées à partir de ces derniers.
PCT/US2001/019220 2000-06-15 2001-06-15 Vaccin contre les tremblements congenitaux du porc WO2001096377A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA002410229A CA2410229A1 (fr) 2000-06-15 2001-06-15 Vaccin contre les tremblements congenitaux du porc
AU2001266940A AU2001266940A1 (en) 2000-06-15 2001-06-15 Vaccine for congenital tremors in pigs
EP01944540A EP1290016A2 (fr) 2000-06-15 2001-06-15 Vaccin contre les tremblements congenitaux du porc
MXPA02012352A MXPA02012352A (es) 2000-06-15 2001-06-15 Vacuna para temblores congenitos en cerdos.
JP2002510517A JP2004503234A (ja) 2000-06-15 2001-06-15 ブタの先天性振せん用ワクチン
US10/311,423 US20040071728A1 (en) 2001-06-15 2001-06-15 Vaccine for congenital tremors in pigs

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21171000P 2000-06-15 2000-06-15
US60/211,710 2000-06-15

Publications (2)

Publication Number Publication Date
WO2001096377A2 WO2001096377A2 (fr) 2001-12-20
WO2001096377A3 true WO2001096377A3 (fr) 2002-06-13

Family

ID=22788038

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/019220 WO2001096377A2 (fr) 2000-06-15 2001-06-15 Vaccin contre les tremblements congenitaux du porc

Country Status (6)

Country Link
EP (1) EP1290016A2 (fr)
JP (1) JP2004503234A (fr)
AU (1) AU2001266940A1 (fr)
CA (1) CA2410229A1 (fr)
MX (1) MXPA02012352A (fr)
WO (1) WO2001096377A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8916353B2 (en) 1997-12-05 2014-12-23 Zoetis W Llc Circovirus sequences associated with piglet weight loss disease (PWD)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040062775A1 (en) 1997-12-05 2004-04-01 Agence Francaise De Securite Sanitaire Des Aliments Circovirus sequences associated with piglet weight loss disease (PWD)
US7276353B2 (en) 2001-12-12 2007-10-02 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
US7279166B2 (en) 2001-12-12 2007-10-09 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
GB0318096D0 (en) * 2003-08-01 2003-09-03 Queen Mary & Westfield College Vaccine
UA95602C2 (ru) 2004-12-30 2011-08-25 Берингер Ингельхейм Ветмедика, Инк. Иммуногенная композиция цвс2 и способы приготовления такой композиции
US7833707B2 (en) 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
HUE033621T2 (en) * 2004-12-30 2017-12-28 Boehringer Ingelheim Vetmedica Inc PCV2 immunogenic compositions and methods for preparing such compositions
US8834891B2 (en) 2005-03-14 2014-09-16 Boehringer Ingelheim Vetmedica, Inc. Immunogenic compositions comprising Lawsonia intracellularis
US7358075B2 (en) * 2005-04-13 2008-04-15 Merial Limited Assay for porcine circovirus production
WO2006132598A1 (fr) * 2005-06-07 2006-12-14 Temasek Life Sciences Laboratory Limited Vaccins contre le circovirus porcin de type 2
US20080226669A1 (en) 2005-12-29 2008-09-18 Boehringer Ingelheim Vetmedica, Inc. Multivalent pcv2 immunogenic compositions and methods of producing such compositions
EP1976558B1 (fr) 2005-12-29 2017-03-15 Boehringer Ingelheim Vetmedica, Inc. Composition immunogène de pcv2 pour la réduction de symptômes cliniques
EP2101815A4 (fr) 2006-12-11 2010-10-06 Boehringer Ingelheim Vetmed Procede efficace de traitement du circovirus porcin et des infections par lawsonia intracellularis
TWI466682B (zh) * 2006-12-15 2015-01-01 Boehringer Ingelheim Vetmed 以豬第二型環狀病毒（ｐｃｖ２）抗原治療豬
EP1941903A1 (fr) 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxie et traitement du PRDC
EP1958644A1 (fr) 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prévention et traitement du PCVD subclinique
US7829274B2 (en) 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
JP5613061B2 (ja) 2008-01-23 2014-10-22 ベーリンガー インゲルハイム フェトメディカ インコーポレイテッド Ｐｃｖ２マイコプラズマ・ハイオニューモニエ免疫原性組成物および前記組成物の製造方法
WO2009093251A2 (fr) * 2008-01-24 2009-07-30 Gavish-Galilee Bio Applications Ltd Vaccin contenant un réovirus basé sur une séquence de protéine sigma c
AR078253A1 (es) 2009-09-02 2011-10-26 Boehringer Ingelheim Vetmed Metodos para reducir la actividad antivirica en composiciones pcv-2 y composiciones pcv-2 con mejor inmunogenicidad
HUP1100470A2 (en) * 2011-08-30 2013-03-28 Mezoegazdasagi Biotechnologiai Kutatokoezpont Nanoparticle-based veterinary vaccine
MX373669B (es) 2013-09-25 2020-04-02 Zoetis Services Llc Composicion de vacuna de circovirus porcino tipo 2b divergente y procedimientos de uso.
KR102409183B1 (ko) 2013-10-02 2022-06-15 베링거 인겔하임 애니멀 헬스 유에스에이 인크. Ｐｃｖ2 ｏｒｆ2 단백질 변이체 및 이로 이루어진 바이러스 유사 입자
CN104109704B (zh) * 2014-07-09 2016-05-04 福州大学 一种重组猪圆环病毒衣壳蛋白包涵体的分离纯化方法
TWI799365B (zh) * 2015-08-31 2023-04-21 德商百靈佳殷格翰維美迪加股份有限公司 用於先天性痙攣症之瘟疫病毒疫苗
CN111087452A (zh) * 2019-12-18 2020-05-01 中国农业科学院兰州兽医研究所 一种猪圆环病毒2b亚型Cap蛋白的原核可溶性表达方法
CN111154915A (zh) * 2020-01-06 2020-05-15 咸阳职业技术学院 一种猪圆环病毒4型与3型pcr鉴别诊断试剂盒及其检测方法
CN112014561B (zh) * 2020-09-03 2022-04-19 扬州大学 猪圆环病毒4型特异的抗原在制备检测猪圆环病毒4型抗体的试剂盒中的应用及试剂盒

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999018214A1 (fr) * 1997-10-03 1999-04-15 Merial Circovirus porcins, vaccins et reactifs de diagnostic
WO1999029717A2 (fr) * 1997-12-11 1999-06-17 University Of Saskatchewan Virus porcins du syndrome de deperissement multisystemique apres sevrage

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999018214A1 (fr) * 1997-10-03 1999-04-15 Merial Circovirus porcins, vaccins et reactifs de diagnostic
WO1999029717A2 (fr) * 1997-12-11 1999-06-17 University Of Saskatchewan Virus porcins du syndrome de deperissement multisystemique apres sevrage

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
B. MEEHAN ET AL.: "Characterisation of novel circovirus DNAs associated with wasting syndromes in pigs", J. GEN. VIROL., vol. 79, 1998, pages 2171 - 2179, XP002194335 *
G. ALLAN ET AL.: "Porcine circoviruses: a review", J. VET. DIAGN. INVEST., vol. 12, 2000, pages 3 - 14, XP001064282 *
G. STEVENSON ET AL.: "Tissue distribution and genetic typing of porcine circoviruses in pigs with naturally ocurring congenital timours", J. VET DIAGN. INVEST, vol. 13, 2001, pages 57 - 62, XP001064291 *
J. TSCHACHTSCHAL ET AL.: "Das Porzine Circovirus - Eine Literaturübersicht", TIERÄRTZLICHE UMSCHAU, vol. 56, - 2001, pages 185 - 198, XP001064247 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8916353B2 (en) 1997-12-05 2014-12-23 Zoetis W Llc Circovirus sequences associated with piglet weight loss disease (PWD)

Also Published As

Publication number Publication date
CA2410229A1 (fr) 2001-12-20
AU2001266940A1 (en) 2001-12-24
JP2004503234A (ja) 2004-02-05
EP1290016A2 (fr) 2003-03-12
WO2001096377A2 (fr) 2001-12-20
MXPA02012352A (es) 2004-09-06

Similar Documents

Publication Publication Date Title
WO2001096377A3 (fr) Vaccin contre les tremblements congenitaux du porc
WO2005021707A3 (fr) Compositions vaccinales d'adn contre le syndrome respiratoire aigu severe et leurs procedes d'utilisation
NZ583028A (en) Nucleic acids and proteins from streptococcus groups A & B
NO329875B1 (no) Isolert DNA-sekvens som koder for svinereproduktive- og respiratoriske syndromvirus (PRRSV), en sammensetning omfattende polypeptidene kodet av denne, en sammensetning for indusering av antistoffer mot PRRSV, anvendelse av sammensetning for fremstilling av vaksine og fremgangsmate for a skille PRRSV-stamme ISU-55 fra andre PRRSV-stammer.
WO2006078318A3 (fr) Compositions immunogenes pour bacteries a gram positif telles que streptococcus agalactiae
NZ549873A (en) Compounds and methods for treatment and diagnosis of chlamydial infection by stimulating an immune response
WO1996010419A3 (fr) Composition comprenant un virus de recombinaison exprimant un antigene et un virus de recombinaison exprimant une molecule immunostimulatrice
WO2001016330A3 (fr) Prevention d'une myocardite, d'un avortement et d'une infection intra-uterine associes au circovirus porcin de type 2
WO2002000242A8 (fr) Traitement des infections par le papillomavirus
NZ319377A (en) polypeptides comprising a portion of a soluble M tuberculosis antigen
WO1999008706A8 (fr) Vecteur d'adenovirus de recombinaison porcin
EE200200507A (et) Muundatud vaktsiiniaviirus Ankara (MVA), sellega nakatatud peremeesrakk ning seda sisaldav farmatseutiline kompositsioon, MVA valmistamine ja raviotstarbeline kasutamine
WO2001089559A3 (fr) Vaccin a poxvirus recombinant contre le virus du syndrome disgenesique respiratoire porcin (vsdrp)
EP1071451A4 (fr) Composes et methodes pour l'immunotherapie et le diagnostic de la tuberculose
AU2003244855A1 (en) Method to enhance an immune response of nucleic acid vaccination
WO2001098460A3 (fr) Proteines de fusion du mycobacterium tuberculosis
WO2003070187A3 (fr) Proteines de fusion de mycobacterium tuberculosis
WO2001045639A3 (fr) Procédés de protection contre l'infection létale par le bacillus anthracis
JP2003500040A5 (fr)
ATE103297T1 (de) Peptid, immunogene zusammensetzung und impfstoff oder medizinische zubereitung, eine methode zur immunisierung eines saeugetieres gegen lhrh und methode zur verbesserung von mea.
GB2324093A (en) Helicobacter pylori bacterioferritin
ATE346931T1 (de) Clostridium perfringens impfstoff
WO2001096370A3 (fr) Antigenes de cryptosporidium parvum, anticorps diriges contres lesdits antigenes et compositions therapeutiques associees
WO2001083739A3 (fr) Polypeptides pellino humains
WO2003013599A3 (fr) Vaccin anti-coronavirus.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2410229

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2002 510517

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/012352

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2001944540

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001944540

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10311423

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2001944540

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载